Form 4: Mineralys CMO Sells Shares After Option Exercise
Insider Transaction Report
Mineralys Therapeutics' Chief Medical Officer, David Rodman, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.
Summary
- Chief Medical Officer David Malcom Rodman exercised stock options to acquire 6,349 shares of Mineralys Therapeutics, Inc. common stock at an exercise price of $1.08 per share on August 12, 2025.
- Following the option exercise, Mr. Rodman sold 11,365 shares of common stock on August 13, 2025, at a weighted-average price of $12.9333 per share.
- The sale price per share ranged from $12.590 to $13.223.
- Both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Rodman on October 25, 2024.
- After these transactions, Mr. Rodman's direct beneficial ownership of common stock stands at 92,891 shares.
- He also beneficially owns 82,531 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The filing reports an insider's pre-planned sale of shares following an option exercise, which is a routine transaction under a Rule 10b5-1 plan. While it represents a reduction in direct ownership, the pre-planned nature mitigates negative sentiment, suggesting a neutral to slightly positive outlook given the profitable exercise.
Positives
- The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not a reaction to immediate negative news.
- The exercise of stock options at a low price ($1.08) and subsequent sale at a significantly higher price ($12.9333) indicates a profitable transaction for the insider.
Negatives
- The net reduction in the Chief Medical Officer's direct common stock holdings (selling 11,365 shares after acquiring 6,349 shares) could be perceived as a slight negative by some investors, despite being pre-planned.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 07/12/2022 | Date when 25% of the underlying stock option shares vested, with remaining shares vesting in 36 substantially equal monthly installments thereafter. |
| 10/25/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 08/12/2025 | Transaction date for the acquisition of common stock via stock option exercise. |
| 08/13/2025 | Transaction date for the disposition (sale) of common stock. |
| 08/14/2025 | Date the Form 4 was signed and filed. |
| 07/11/2032 | Expiration date of the stock option. |
Recommendation
holdThe filing details a pre-planned insider sale by the Chief Medical Officer following an option exercise. Such transactions, executed under a Rule 10b5-1 plan, are typically not indicative of a change in management's outlook on the company's prospects and are often for personal financial planning. Therefore, it does not provide a strong signal for a buy or sell recommendation, suggesting a 'hold' stance.
Keywords
Mineralys Therapeutics, MLYS, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Chief Medical Officer, David Rodman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.